Patent ID: RE40245

Claim:
A compound of formula IIa or IIb: or a pharmaceutically acceptable salt thereof, wherein: W is nitrogen or CR a ; R a is selected from hydrogen, halogen, —CF 3 , R 7 , —OR 7 , or —N(R 7 ) 2 ; R 1 is an aryl or heteroaryl ring, wherein said ring is optionally substituted by up to four R 9 ; wherein an R 9 substituent in the ortho-position of R 1 taken together with R 2 may form a fused, unsaturated or partially unsaturated, optionally substituted 5-8 membered ring having 0-2 ring heteroatoms selected from nitrogen, oxygen, or sulfur; R 2 and R 3 are each independently selected from R 6 , halogen, CN, SR 6 , OR 6 , N(R 6 ) 2 , NRCO 2 R 6 , NRCON (R 6 ) 2 , CON(R 6 ) 2 , NRCOR 6 , NRN(R 6 ) 2 , COR 6 , CO 2 R 6 , COCOR 6 , SO 2 R 6 , SO 2 N(R 6 ) 2 , or NRSO 2 R 6 ; or R 2 and R 3 are taken together to form a fused, unsaturated or partially unsaturated, optionally substituted 5-8 membered ring containing 0-2 ring heteroatoms selected from nitrogen, oxygen, or sulfur; R 4 is selected from R 6 , CON(R 6 ), COR 6 , CO 2 R 6 , COCOR 6 , SO 2 R 6 , SO 2 N(R 6 ) 2 , or (CH 2 ) y R 2 ; y is 1-6; each R is independently selected from hydrogen or an optionally substituted aliphatic group having one to six carbons; Ar is a five membered heteroaryl, heterocyclyl, or carbocyclyl ring, wherein said ring is optionally substituted by up to three substituents selected from oxo, halogen, CN, NO 2 , R 8 , OR 8 , NHR 8 , NHCOR 8 , NHCONHR 8 , COR 8 , CONHR 8 , SO 2 R 8 , NHSO 2 NHR 8 or SO 2 NHR 8 ; each R 6 is independently selected from R 7 or an optionally substituted group selected from alkoxy, hydroxyalkyl, heterocyclyl, heterocyclcylalkyl heterocyclylalkyl , aryl, aralkyl, aralkoxy, aryloxyalkyl, heteroaryl, heteroaralkyl, heteroaralkoxy, or heteroarayloxyalkyl heteroaryloxyalkyl ; each R 7 is independently selected from hydrogen or an optionally substituted aliphatic group having one to six carbons, or two R 7 on the same nitrogen taken together with the nitrogen optionally form a four to six member, saturated or unsaturated heterocyclic ring having one to three heteroatoms; R 8 is a C 1 -C 4 aliphatic group , wherein two R 8 on adjacent positions of Ar, or an aryl or heteroaryl ring, may be taken together with their intervening atoms to form a three to six membered fused ring ; each R 9 is independently selected from oxo, halogen, CN, NO 2 , T n (haloalkyl), R 6 , SR 6 , OR 6 , OR 8 , N(R 6 ) 2 , CON (R 6 ) 2 , CON(R)COR 6 , COR 6 , CO 2 R 6 , CO 2 N(R 6 ) 2 , COCOR 6 , SO 2 R 6 , SO 2 N(R 6 ) 2 , N(R)T n CO 2 R 6 , N(R) T n CON(R 6 ) 2 , N(R)T n N(R 6 ) 2 , N(R)T n NRCO 2 R 6 , N(R) T n NRCON(R 6 ) 2 , N(R)T n COR 6 , N(R)T N NRCOR 6 N( R ) T n NRCOR 6 , N(R)T n SO 2 N(R 6 ) 2 , N(R)T n SO 2 R 6 , T n PO(OR 7 ) 2 , T n OPO(OR 7 ) 2 , T n SP(OR 7 ) 2 , T n PO(OR 7 ) 2 , or T n NPO (OR 7 ) 2 ; each Q is an independently selected C 1 -C 3 branched or straight alkyl; T is selected from —Q— or —Q m —CH(Q m —R 2 )—; and each m and n are independently selected from zero or one.